Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

162.30 +2.62 (+1.64%)
Official Closing Price Updated: 7:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
99 100 Next >
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: 
Via Benzinga
If You Can Only Buy One Dividend Stock in April, It Better Be One of These 3 Names
The economy is performing pretty well, investing in these top dividend stocks to buy will guarantee good profits. 
Via InvestorPlace
Topics Economy
Exposures Economy
Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?
The company is hoping to expand, but is there enough here to attract growth investors? 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Assessing Johnson &amp; Johnson's Performance Against Competitors In Pharmaceuticals Industry
Via Benzinga
2 Dividend Stocks to Buy and Hold Forever
These dividends are about as safe as they come. 
Via The Motley Fool
Why NYSE:JNJ provides a good dividend, while having solid fundamentals.
Balancing Dividends and Fundamentals: The Case of JOHNSON & JOHNSON (NYSE:JNJ). 
Via Chartmill
Looking Into Johnson & Johnson's Recent Short Interest
Via Benzinga
How's AT&T Handling Things?
We've also got a look at 3M's spinoff, gold prices, and the beef industry. 
Via The Motley Fool
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
Income-seeking investors can look forward to steady payout raises from these pharma stocks. 
Via The Motley Fool
Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration... 
Via Benzinga
Exposures Product Safety
Johnson & Johnson's $13B Shockwave Medical Deal Accelerates MedTech Strategy, Analyst Says
Johnson & Johnson acquires Shockwave Medical, bolstering its presence in cardiovascular intervention. The move marks a strategic shift, with around $30 billion invested in MedTech over 18 months. 
Via Benzinga
Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?
Johnson & Johnson's proposed acquisition of Shockwave Medical may be the jolt that JNJ stock needs to break out of a year-long downtrend 
Via MarketBeat
Grow Your Bottom Line As Demand Increases For These Robots
Today, I’ll explain why there’s a growing need for more robots to do surgery. I’ll also show you how to collect a reliable yield while investing in a company that’s developing new surgical robots. 
Via Talk Markets
Can a New CEO Fix Boeing?
We also talk with e.l.f. Beauty CEO Tarang Amin about how the company is succeeding. 
Via The Motley Fool
The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024
With risk-on sentiment in place, investors may be looking for the most undervalued Russell 2000 stocks to buy in April. 
Via InvestorPlace
SWAV Stock Alert: Shockwave Medical Lands Big Buyer in Johnson & Johnson
JNJ is building a suite of heart disease treatment devices and hopes integration can help it avoid a patent cliff. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Johnson & Johnson Makes Yet Another Multi-Billion MedTech Deal With Shockwave Medical
Johnson & Johnson to acquire Shockwave Medical for $335.00/share in cash, bolstering its cardiovascular intervention portfolio. The acquisition, expected to close by mid-2024, signifies Johnson &... 
Via Benzinga
Johnson & Johnson To Buy Shockwave Medical For $13.1 Billion
The Dow giant will pay $335 a share for Shockwave following takeover buzz. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Johnson & Johnson to Acquire Shockwave Medical
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
From Johnson & Johnson
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Rich Returns at a Discount: 3 Dividend Aristocrats Trading at 52-Week Lows
Want quality picks and reliable income at a discount? Check out these Dividend Aristocrats trading at 52-week lows. 
Via InvestorPlace
5 Things to Know in Investing This Week
The Shockwave Issue 
Via Benzinga
Johnson & Johnson to Participate in the BofA Securities Health Care Conference
From Johnson & Johnson
Via Business Wire
Russell 2000 Index Best And Worst Performing Stocks Of 2024
The Russell 2000 index continued to underperform the Dow Jones and Nasdaq 100 indices in the first quarter of 2024. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Why 3M Stock Was Moving Higher Today
Investors applauded the spin-off of its healthcare business. 
Via The Motley Fool
2024 S&P 500 Bull Market: 2 Unstoppable Growth Stocks to Buy Right Now
The fresh bull market is attracting investors of all trading styles. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Reliable Dividend Growth Stocks With Yields Above 3% That You Can Buy Now and Hold for at Least a Decade
These advantaged businesses have what it takes to keep raising their payouts. 
Via The Motley Fool
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.